Opportunity Information: Apply for PA 14 084
Apply for PA 14 084
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Neuroimmune Signaling in Substance Use Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 4, 2014 and posted on Feb 4, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Small businesses County governments Private institutions of higher education Special district governments Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Neuroimmune Signaling in Substance Use Disorders (R01) funding opportunity (PA-14-084) was a National Institutes of Health (NIH) research project grant announcement designed to push more research into how immune-related signaling inside the central nervous system influences substance use disorders (SUDs). The core idea behind the FOA is that neuroimmune pathways in the brain and spinal cord are still relatively understudied in addiction science, even though growing evidence suggests they can shape how drug use starts, how it escalates, how it becomes compulsive, and what long-term neurological consequences follow. The announcement called for R01 applications that directly investigate neuroimmune signaling across multiple levels of analysis, ranging from molecular and cellular mechanisms to neural circuits and measurable behavior.
Scientifically, the FOA emphasized studies that connect neuroimmune activity to the full addiction cycle. That includes the initiation of drug use, the escalation and maintenance of problematic use, and the brain-related consequences that may persist during or after active use. It also explicitly included the abstinence phase, withdrawal processes, and relapse risk after periods without drug use. In practical terms, applicants were being encouraged to frame addiction not only as a problem of neurotransmitters and reward circuitry, but also as a condition influenced by immune-like signaling in the CNS, such as inflammatory mediators and immune cell interactions within brain tissue, and to clarify whether those responses worsen outcomes or, in some situations, protect the brain and reduce risk.
A major goal of the opportunity was to determine the extent to which neuroimmune responses either contribute to vulnerability and harm (for example, driving maladaptive plasticity, stress responsiveness, negative affect, or cognitive impairment) or serve protective roles (for example, limiting damage, promoting recovery, or reducing relapse susceptibility). The FOA was broad in scope about what approaches could be used, as long as the work addressed neuroimmune signaling in the CNS in relation to SUD processes and outcomes. This typically implies interest in mechanistic work that can link changes in signaling pathways or cell states to circuit function and behavior, rather than purely descriptive observations without a clear connection to addiction-relevant endpoints.
Administratively, this was a discretionary grant opportunity using the NIH R01 mechanism, listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs). It did not require cost sharing or matching. The announcement was posted on February 4, 2014, and the final application due date was May 7, 2017, after which it was archived on June 7, 2017. While the FOA is no longer open, it provides a clear picture of NIH priorities at the time: advancing addiction research by integrating neuroscience with neuroimmunology to better explain risk, persistence, and relapse.
Eligibility was expansive and included a wide range of domestic U.S. applicants, such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), state and local governments (including counties, cities/townships, special districts, and independent school districts), public housing authorities/Indian housing authorities, and tribal governments and tribal organizations. It also explicitly allowed non-U.S. participation: foreign organizations and foreign institutions could apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined by NIH policy) were permitted. The FOA also highlighted eligibility for a number of institution types and community-focused entities, including HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and eligible federal agencies.
For further details, the announcement pointed to the NIH Grants Guide page for PA-14-084 (http://grants.nih.gov/grants/guide/pa-files/PA-14-084.html) and provided NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues (FBOWebmaster@OD.NIH.GOV).
FAQs: Neuroimmune Signaling in Substance Use Disorders (R01) - PA-14-084
What was PA-14-084 (Neuroimmune Signaling in Substance Use Disorders) designed to fund?
PA-14-084 was an NIH research project grant (R01) funding opportunity focused on advancing research into how immune-related signaling within the central nervous system (CNS) influences substance use disorders (SUDs). The central purpose was to encourage studies that link neuroimmune pathways in the brain and spinal cord to addiction-relevant processes and outcomes.
Which NIH grant mechanism did this opportunity use?
This opportunity used the NIH R01 mechanism (Research Project Grant), and it was described as a discretionary grant opportunity.
What was the scientific premise behind the FOA?
The FOA emphasized that neuroimmune signaling in the CNS was relatively understudied in addiction science, despite growing evidence that it may shape how drug use begins, how it escalates, how it becomes compulsive, and what long-term neurological consequences may occur during or after use.
What types of research questions were encouraged under this FOA?
The announcement encouraged applications that directly investigate neuroimmune signaling across multiple levels of analysis, including molecular and cellular mechanisms, neural circuits, and measurable behavior, specifically in relation to SUD processes and outcomes.
How broadly did the FOA define the addiction cycle for study purposes?
The FOA highlighted the full addiction cycle, including initiation of drug use, escalation and maintenance of problematic use, development of compulsive use, and neurological consequences. It also explicitly included abstinence, withdrawal processes, and relapse risk after periods without drug use.
Did the FOA only focus on reward circuitry and neurotransmitters?
No. A practical theme of the FOA was to encourage applicants to frame addiction not only as a neurotransmitter and reward-circuit problem, but also as a condition influenced by immune-like signaling within the CNS, such as inflammatory mediators and immune cell interactions in brain tissue.
What kinds of neuroimmune factors were within scope?
Based on the description provided, the FOA was interested in neuroimmune signaling in the brain and spinal cord, including inflammatory mediators and immune cell interactions within brain tissue, as long as these factors were connected to SUD processes and outcomes.
Was the FOA interested in harmful neuroimmune effects, protective effects, or both?
Both. A major goal was to determine the extent to which neuroimmune responses contribute to vulnerability and harm (for example, maladaptive plasticity, stress responsiveness, negative affect, or cognitive impairment) versus serve protective roles (for example, limiting damage, promoting recovery, or reducing relapse susceptibility).
What kind of study design emphasis can be inferred from the FOA description?
The FOA was described as broad in allowable approaches, but it typically implied interest in mechanistic work that can link signaling pathways or cell states to circuit function and behavior, rather than purely descriptive observations that do not clearly connect to addiction-relevant endpoints.
Did the FOA require the research to span multiple levels (molecular to behavior)?
The FOA called for R01 applications that investigate neuroimmune signaling across levels ranging from molecular and cellular mechanisms to neural circuits and measurable behavior. The description indicates NIH interest in connecting findings across these levels, when appropriate to the project.
What is the CFDA number associated with this opportunity?
The opportunity was listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Was cost sharing or matching required?
No. The FOA explicitly stated that it did not require cost sharing or matching.
When was the FOA posted, and what were the key dates?
The announcement was posted on February 4, 2014. The final application due date was May 7, 2017. The FOA was archived on June 7, 2017.
Is PA-14-084 still open for applications?
No. The FOA is no longer open; it was archived after the final due date in 2017.
What does it mean that the FOA is archived?
Based on the information provided, “archived” indicates the opportunity is no longer accepting applications and is maintained as a historical record of NIH priorities and the prior solicitation details.
Who was eligible to apply (U.S. applicants)?
Eligibility was broad and included many domestic U.S. applicants, including public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and state and local government entities (including counties, cities/townships, special districts, and independent school districts).
Were tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations were explicitly listed among eligible applicants.
Were public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities were explicitly included in the eligibility list.
Could foreign organizations apply?
Yes. The FOA explicitly allowed non-U.S. participation, including foreign organizations and foreign institutions.
Were non-U.S. components of U.S. organizations eligible?
Yes. Non-U.S. components of U.S. organizations were eligible under this FOA.
Were foreign components permitted under NIH policy?
Yes. The FOA stated that foreign components (as defined by NIH policy) were permitted.
Which institution types were specifically highlighted as eligible?
The FOA highlighted eligibility for a number of institution types and community-focused entities, including HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations.
Were U.S. territories or possessions included in the eligibility discussion?
Yes. U.S. territories or possessions were referenced as eligible entities in the eligibility description provided.
Were regional organizations and federal agencies included as potentially eligible?
Yes. The eligibility description included regional organizations and eligible federal agencies.
Where could applicants find the official NIH listing for PA-14-084?
The FOA pointed to the NIH Grants Guide page for PA-14-084 at http://grants.nih.gov/grants/guide/pa-files/PA-14-084.html.
Who should be contacted for access or linking issues related to the announcement?
The FOA provided NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues: FBOWebmaster@OD.NIH.GOV.
What broader NIH research priority did this FOA illustrate?
Based on the description provided, the FOA reflected a priority to advance addiction research by integrating neuroscience with neuroimmunology to better explain risk, persistence, and relapse in substance use disorders.
Browse more opportunities from the same category: Education Health
Next opportunity: Neuroimmune Signaling and Function in Substance Use Disorders (R21)
Previous opportunity: Building Energy Efficiency Frontiers and Incubator Technologies (BENEFIT) 2014
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 084
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 084) also looked into and applied for these:
| Funding Opportunity |
|---|
| Neuroimmune Signaling and Function in Substance Use Disorders (R21) Apply for PA 14 083 Funding Number: PA 14 083 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01) Apply for PAR 14 085 Funding Number: PAR 14 085 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01) Apply for PAR 14 086 Funding Number: PAR 14 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 084", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.